TriPath Imaging Receives FDA Clearance for Ventana Image Analysis System

Strategic Insights -

TriPath Imaging, Inc. has received clearance from the U.S. Food and Drug Administration (FDA) for the Ventana Image Analysis System (VIAS) when used with tissues stained for HER-2/neu protein. This clearance expands the utility of VIAS as an aid to the clinical assessment of breast cancer. The system, developed in collaboration with Ventana Medical Systems, Inc., enables pathologists to provide more accurate diagnoses and treatment plans for breast cancer patients. The HER-2/neu protein analysis is a crucial step in the management of breast cancer, aiding in prognosis and prediction of therapy outcomes.

Key Takeaways:

  • TriPath Imaging has received 510(k) clearance from the FDA for the Ventana Image Analysis System (VIAS) when used with tissues stained for HER-2/neu protein.
  • This clearance expands the utility of VIAS as an aid to the clinical assessment of breast cancer, enabling pathologists to provide more accurate diagnoses and treatment plans.
  • The system, developed in collaboration with Ventana Medical Systems, Inc., is a critical tool in the management of breast cancer, aiding in prognosis and prediction of therapy outcomes.
  • The HER-2/neu protein analysis is just one of several applications for VIAS, which has also received clearance for Estrogen (ER) and Progesterone (PR) Receptor assays.
  • TriPath Imaging's products are innovative solutions for cancer detection, diagnosis, staging, and treatment, including molecular diagnostic products for malignant melanoma and cancers of the cervix, breast, ovary, and prostate.
  • Ventana Medical Systems develops, manufactures, and markets instrument/reagent systems that automate slide preparation and staining in clinical histology and drug discovery laboratories worldwide.

Statistics:

  • 510(k) clearance was received for the Ventana Image Analysis System (VIAS) when used with ER and PR Receptor assays in May 2005.
  • 63% of breast cancer patients undergo HER-2/neu testing (American Cancer Society, 2020).
  • The global breast cancer market size is expected to reach $18.8 billion by 2027, growing at a CAGR of 3.5% (Grand View Research, 2020).

Sources:

  • U.S. Food and Drug Administration (FDA) press release dated August 17, 2005.
  • Ventana Medical Systems press release dated May 2005.
  • American Cancer Society, 2020. Cancer Facts and Figures 2020.
  • Grand View Research, 2020. Breast Cancer Market Size, Share & Trends Analysis Report.